Aptevo Therapeutics Inc (APVO) Stock Price, Quote & News

Company Profile

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 838 0500

Fax: 206 838 0503

Website: aptevotherapeutics.com

Address:

2401 4th Avenue, Suite 1050, Seattle, United States

tommycman Jun. 16 at 12:49 PM

$APVO wonderful,Ijust bought in this at $4.32 an 1 minute later this news is out of filing to sell 1.7 million shares! Is this an offering (now) or just registering to sell (in the near future)? Is this immediately bullish or bearish (imminent catalyst PR or what)? Grrh!

0 · Reply

DonCorleone77 Jun. 16 at 12:27 PM

$APVO Aptevo Therapeutics files to sell 1.71M shares of common stock, warrants Roth Capital Partners is exclusive placement agent.

0 · Reply

macstock Jun. 16 at 9:52 AM

$APVO biggest turd on the tickers

0 · Reply

BulldogTheDip Jun. 16 at 1:04 AM

BullTheDip Report: 3-Month Fallen Angels 🐋 A few I am watching this week; they are wrecked but ripe — all down 90%+ with micro floats & catalysts: 🔹 $FMTO ($4.61, -99.5%, 0.7M float) Buy: ≤ $4.70 │ Target: $6.50 │ Stop: $4.05 │ Risk: High ▶️ Buyback approved, ultra-low float = explosive potential on volume. 🔹 $APVO ($4.39, -91.6%, 0.66M float) Buy: ≤ $4.50 │ Target: $6.25 │ Stop: $3.80 │ Risk: Medium-High ▶️ BIO International this week — any collab PR could ignite it. 🔹 $STSS ($5.45, -94.3%, 1.0M float) Buy: ≤ $5.60 │ Target: $8.00 │ Stop: $4.85 │ Risk: Medium ▶️ Smart-syringe spotlight + biotech momentum = solid swing setup. ⚠️ All plays sized by risk. Tight stops. No bag-holding. Let the whales eat. #WHALEME #BullysofStocktwits #SwingTrading #PennyStocks #FallenAngels

0 · Reply

sixfigures718 Jun. 13 at 8:44 PM

$APVO $BATL $EONR $HUSA $OP

0 · Reply

ItTakesItAll Jun. 13 at 8:29 PM

$APVO Adding, very careful ok? they regain compliance and news is coming, tiny float + volume will take it home.

1 · Reply

experttrade Jun. 13 at 8:26 PM

$APVO something strange going on here

2 · Reply

Dreamer89 Jun. 13 at 8:24 PM

$APVO Just now went red and lost all gains. Booooooom richhhh in minutes while these bafoons trying short oil stocks all day and getting smoked. 👍👍👍👍👍🤣🤑🤑🤑🤑😎

0 · Reply

DaBullRunner Jun. 13 at 8:23 PM

$EONR how is this not running off $BATL $OP $HUSA ??? $APVO moving AH no news

0 · Reply

makedatbread88 Jun. 13 at 8:12 PM

$APVO low float, participating in conference next week, did a reverse split on May 23rd roughly 655k float looks like https://www.stocktitan.net/news/APVO/aptevo-participating-in-the-bio-international-ecxrea3nrovw.html

0 · Reply

Aptevo Participating in the BIO International Convention

May 22, 2025, 8:05 AM EDT - 25 days ago

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

May 15, 2025, 8:05 AM EDT - 4 weeks ago

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

May 8, 2025, 8:45 AM EDT - 5 weeks ago

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

Apr 22, 2025, 4:05 PM EDT - 7 weeks ago

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 21, 2025, 2:40 PM EDT - 2 months ago

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 4, 2025, 4:05 PM EDT - 2 months ago

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 3, 2025, 8:50 AM EDT - 2 months ago

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Mar 20, 2025, 8:35 AM EDT - 3 months ago

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Mar 18, 2025, 8:05 AM EDT - 3 months ago

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Mar 6, 2025, 8:00 AM EST - 3 months ago

Aptevo to Participate in March Conferences

Feb 15, 2025, 6:59 PM EST - 4 months ago

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Feb 14, 2025, 8:05 AM EST - 4 months ago

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

Jan 15, 2025, 8:00 AM EST - 5 months ago

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Dec 12, 2024, 12:50 PM EST - 6 months ago

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

Dec 12, 2024, 9:00 AM EST - 6 months ago

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Dec 4, 2024, 8:35 AM EST - 6 months ago

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Nov 29, 2024, 9:55 AM EST - 7 months ago

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

Nov 26, 2024, 8:35 AM EST - 7 months ago

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Nov 22, 2024, 8:35 AM EST - 7 months ago

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

Nov 20, 2024, 8:35 AM EST - 7 months ago

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

Nov 11, 2024, 8:15 AM EST - 7 months ago

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Nov 7, 2024, 8:05 AM EST - 7 months ago

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Sep 18, 2024, 4:05 PM EDT - 9 months ago

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Sep 16, 2024, 8:05 PM EDT - 9 months ago

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Aug 13, 2024, 8:05 AM EDT - 10 months ago

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aug 8, 2024, 8:05 AM EDT - 11 months ago

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Jul 1, 2024, 4:20 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

Jun 28, 2024, 9:20 AM EDT - 1 year ago

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

May 14, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

May 8, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

Apr 15, 2024, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering

Apr 10, 2024, 9:00 AM EDT - 1 year ago

Aptevo Therapeutics Provides Pipeline Update

Mar 18, 2024, 6:00 AM EDT - 1 year ago

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

Mar 5, 2024, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update

Mar 4, 2024, 9:00 AM EST - 1 year ago

Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan

Nov 14, 2023, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update

Nov 1, 2023, 7:45 AM EDT - 1 year ago

Aptevo to Present at Bio-Europe Conference

Aug 10, 2023, 8:05 AM EDT - 2 years ago

Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update

Aug 4, 2023, 6:40 PM EDT - 2 years ago

Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering

Aug 1, 2023, 10:15 PM EDT - 2 years ago

Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering

Jul 18, 2023, 8:05 AM EDT - 2 years ago

Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML

May 11, 2023, 8:05 AM EDT - 2 years ago

Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update

Mar 30, 2023, 7:45 AM EDT - 2 years ago

Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update

Mar 30, 2023, 7:30 AM EDT - 2 years ago

Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding

Jan 9, 2023, 8:05 AM EST - 2 years ago

Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors

Dec 12, 2022, 8:37 AM EST - 2 years ago

Aptevo's stock rallies 107% after sharing preliminary data about experimental leukemia treatment

Dec 12, 2022, 7:35 AM EST - 2 years ago

100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)

Nov 10, 2022, 8:05 AM EST - 2 years ago

Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

tommycman Jun. 16 at 12:49 PM

0 · Reply

DonCorleone77 Jun. 16 at 12:27 PM

$APVO Aptevo Therapeutics files to sell 1.71M shares of common stock, warrants Roth Capital Partners is exclusive placement agent.

0 · Reply

macstock Jun. 16 at 9:52 AM

$APVO biggest turd on the tickers

0 · Reply

BulldogTheDip Jun. 16 at 1:04 AM

0 · Reply

sixfigures718 Jun. 13 at 8:44 PM

$APVO $BATL $EONR $HUSA $OP

0 · Reply

ItTakesItAll Jun. 13 at 8:29 PM

$APVO Adding, very careful ok? they regain compliance and news is coming, tiny float + volume will take it home.

1 · Reply

experttrade Jun. 13 at 8:26 PM

$APVO something strange going on here

2 · Reply

Dreamer89 Jun. 13 at 8:24 PM

$APVO Just now went red and lost all gains. Booooooom richhhh in minutes while these bafoons trying short oil stocks all day and getting smoked. 👍👍👍👍👍🤣🤑🤑🤑🤑😎

0 · Reply

DaBullRunner Jun. 13 at 8:23 PM

$EONR how is this not running off $BATL $OP $HUSA ??? $APVO moving AH no news

0 · Reply

makedatbread88 Jun. 13 at 8:12 PM

0 · Reply

Dreamer89 Jun. 13 at 8:11 PM

$APVO loll spiked 2$ in news that they are participating in a conference next week. Lololol caught the top... Half out... Waiting for dump on this stupid pump. Another micro float spike like $ALZN yesterday that went red 😎😎👍🤑🤑🤑🤑

0 · Reply

Vertic Jun. 13 at 8:08 PM

$APVO

0 · Reply

AlertsAndNews Jun. 13 at 8:06 PM

$APVO getting some hits here in after hours.

0 · Reply

Moe_cash Jun. 13 at 8:05 PM

$APVO hello hello

0 · Reply

backjackreturnes1 Jun. 12 at 9:48 PM

$APVO

0 · Reply

macstock Jun. 12 at 3:41 AM

$APVO all of these pumpers coming out of nowhere lol. Don’t fall for it. Management has scammed enough money from people on this one already….. don’t need a bunch pump and dump trolls to do it too…..

0 · Reply

DarkLens Jun. 11 at 10:27 PM

$APVO $BON $FAST $CNEY watch $JAGX It's a known runner and beaten down

0 · Reply

DavidDayTrade Jun. 11 at 6:47 PM

$APVO just wait for the bomb

1 · Reply

makedatbread88 Jun. 11 at 2:13 PM

$APVO this one since its reverse split still hasn’t had any sort of news If company ever dropped any positive news this would fly with its super low float

1 · Reply

MicrocapCowboy Jun. 9 at 3:47 PM

$APVO this is kind of a big day....a close above $1 today brings APVO back into NASADAQ compliance. If anyone or any institution intends to buy and hold a large position, they were going to want to do so only after regaining compliance.

1 · Reply

parkerbeck Jun. 6 at 5:09 PM

$APVO drop some news!

0 · Reply

buttermeupalready Jun. 3 at 3:45 PM

$APVO $RNAZ $BSLK $PTIX Time to buy reverse split junkies and sell the news push

1 · Reply

Market Cap	1.78M
Revenue (ttm)	0.00
Net Income (ttm)	-24.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	146,700
Avg Vol	320,474
Day's Range	N/A - N/A
Shares Out	405,000.00
Stochastic %K	10%
Beta	5.75
Analysts	Strong Sell
Price Target	$420.00